πŸ”¬Deep Research

CNSP β€” Cns Pharmaceuticals Inc Β· catalysts, narrative & risks

Β·20 sourcesCNSP forecast β†’

Overview

As of the snapshot date (October 19, 2026 close), CNS Pharmaceuticals (NASDAQ:CNSP) trades at approximately $4.99, with a 52-week range of $1.90–$10.54 and a roughly 45.8% one-year return [20]. It is a micro-cap biotechnology company in the Healthcare/Biotechnology sector, headquartered in Houston, Texas, pursuing therapies for neurology and oncology [17]. Reported market cap sits at roughly $7.09M–$7.29M depending on the provider and date, though one aggregator lists as low as $1.74Mβ€”indicating notable inconsistency in share-count/market-cap data across sources [15][20]. The company generates no meaningful revenue and has posted persistent, large quarterly losses [20].

Recent Catalysts (last ~1–3 months)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’